Repaglinide

Category: pharmacological

Aliases: Prandin

Pharmacological Mechanism

Meglitinide — closes pancreatic β-cell K-ATP channels (same target as sulfonylureas, distinct binding site) → insulin release. Short half-life supports pre-prandial dosing for post-prandial glucose control. Hepatic CYP2C8 + CYP3A4 substrate.

Half-Life (t½)

PO: 1h

Dosing Guidelines

• PO: Typical 1 mg (Range: 0.5–16 mg)

Target Organ Systems

• endocrine
• digestive

Pathways It Modulates

• Insulin signaling + glucose homeostasis (activator) — KATP channel block (SUR1, distinct site from sulfonylureas)

Chemical Identifiers

• PubChem CID: 65981
• Formula: C27H36N2O4
• Molecular weight: 452.59 g/mol
• InChIKey: FAEKWTJYAYMJKF-QHCPKHFHSA-N
• SMILES: CCOC1=C(C=CC(=C1)CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O

References

• PMID 10501822